Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Shares Outstanding for 12 consecutive years, with $28.5 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 10.06% year-over-year to $28.5 million; the TTM value through Mar 2026 reached $28.5 million, up 10.06%, while the annual FY2025 figure was $26.0 million, 0.95% up from the prior year.
  • Shares Outstanding hit $28.5 million in Q1 2026 for Cartesian Therapeutics, up from $26.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $153.0 million in Q3 2022 and bottomed at $5.1 million in Q4 2022.
  • Average Shares Outstanding over 5 years is $38.9 million, with a median of $25.8 million recorded in 2024.
  • Year-over-year, Shares Outstanding tumbled 96.65% in 2023 and then skyrocketed 377.39% in 2024.
  • Cartesian Therapeutics' Shares Outstanding stood at $5.1 million in 2022, then grew by 5.8% to $5.4 million in 2023, then skyrocketed by 377.39% to $25.8 million in 2024, then grew by 0.95% to $26.0 million in 2025, then grew by 9.74% to $28.5 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $28.5 million, $26.0 million, and $26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.